Arthritis Drug Shows Promise for Ulcerative Colitis – U.S. News & World Report

Arthritis Drug Shows Promise for Ulcerative ColitisU.S. News & World Report”There is still a substantial unmet need for new treatments for patients with ulcerative colitis,” said study lead author Dr. William Sandborn. He is professor of medicine and chief of the division of gastroenterology at the University of California …Xeljanz beats placebo in three ulcerative colitis trialsHealioPhase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of …Yahoo Financeall 5 news articles » FULL ARTICLE: http://zpr.io/PFzf4

Read More

Endoscopic needle knife stricturotomy safe, effective for treating strictures in IBD

A novel endoscopic procedure called needle knife stricturotomy was safe and effective for treating strictures in a study of patients with inflammatory bowel disease, and thus may provide an alternative to endoscopic balloon dilation and surgery.“We pioneered this procedure,” Bo Shen, MD, medical director of Cleveland Clinic’s IBD Center, said in a press release. “Our research shows that it is effective and can have advantages over other conventionally used treatments, such as medical therapy, balloon dilation and surgery.” FULL ARTICLE: http://zpr.io/P3eCf

Read More

Single FMT appears safe, effective for increasing microbial diversity in UC

A single fecal microbiota transplantation via colonoscopy appeared safe and effective for increasing microbial diversity in patients with active ulcerative colitis, according to the results of a prospective, open-label pilot study.“Patients with ulcerative colitis typically have a lower diversity of microbes in their guts,” Randy S. Longman, MD, an assistant professor of medicine at Weill Cornell Medicine and a gastroenterologist at NewYork-Presbyterian/Weill Cornell Medical Center, said in a press release. “We know that a more diverse microbiota is correlated with better health, so increasing that diversity may be a key…

Read More

FDA approves biosimilar for infliximab

Today, the FDA has approved Merck and Samsung Bioepis’ infliximab biosimilar for injection, which is known as infliximab-abda (Renflexis). It will maintain the same indications as the reference product.Infliximab (Remicade, Johnson & Johnson) is indicated for Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. FULL ARTICLE: http://zpr.io/P3HsF

Read More
<< Go Back